血液透析不影响硝苯地平的药代动力学。
Haemodialysis does not affect the pharmacokinetics of nifedipine.
作者信息
Martre H, Sari R, Taburet A M, Jacobs C, Singlas E
出版信息
Br J Clin Pharmacol. 1985 Aug;20(2):155-8. doi: 10.1111/j.1365-2125.1985.tb05049.x.
Abstract
To establish dosage recommendations in patients with end-stage renal disease undergoing chronic haemodialysis, nifedipine kinetics were studied between and during haemodialysis sessions. In eight patients, during the interdialytic period, peak plasma concentrations of nifedipine (29-332 ng/ml) were reached 0.5-1.0 h after administration of a single 10 mg oral dose. Elimination half-life and oral plasma clearance were respectively 2.6 +/- 0.5 h and 1 176 +/- 412 ml/min. Nifedipine plasma protein binding was decreased in uraemic patients (88.8 +/- 0.3% vs 94.4 +/- 0.1%) but not affected by haemodialysis. Removal by haemodialysis was low: the dialyser extraction ratio and the dialysis clearance were respectively 2.3 +/- 0.8% and 2.8 +/- 0.9 ml/min.
摘要
为了确定接受慢性血液透析的终末期肾病患者的用药剂量建议，研究了血液透析期间及透析间期硝苯地平的动力学。在8名患者中，透析间期单次口服10mg剂量后，硝苯地平的血浆峰值浓度（29 - 332ng/ml）在给药后0.5 - 1.0小时达到。消除半衰期和口服血浆清除率分别为2.6±0.5小时和1176±412ml/分钟。尿毒症患者硝苯地平的血浆蛋白结合率降低（88.8±0.3%对94.4±0.1%），但不受血液透析影响。血液透析清除率较低：透析器提取率和透析清除率分别为2.3±0.8%和2.8±0.9ml/分钟。
相似文献
1
Haemodialysis does not affect the pharmacokinetics of nifedipine.血液透析不影响硝苯地平的药代动力学。
Br J Clin Pharmacol. 1985 Aug;20(2):155-8. doi: 10.1111/j.1365-2125.1985.tb05049.x.
2
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.终末期肾病血液透析患者依度沙班的药代动力学、安全性和耐受性。
Thromb Haemost. 2015 Apr;113(4):719-27. doi: 10.1160/TH14-06-0547. Epub 2015 Jan 8.
3
Influence of haemodialysis on the pharmacokinetics and haemodynamic effects of nifedipine during continuous intravenous infusion.血液透析对持续静脉输注硝苯地平的药代动力学及血流动力学效应的影响。
Clin Pharmacokinet. 1986 Jul-Aug;11(4):316-22. doi: 10.2165/00003088-198611040-00004.
4
Pharmacokinetics of ornidazole in patients with renal insufficiency; influence of haemodialysis and peritoneal dialysis.奥硝唑在肾功能不全患者中的药代动力学；血液透析和腹膜透析的影响。
Br J Clin Pharmacol. 1985 Feb;19(2):211-7. doi: 10.1111/j.1365-2125.1985.tb02633.x.
5
Disposition and removal of metronidazole in patients undergoing haemodialysis.血液透析患者中甲硝唑的处置与清除
Eur J Clin Pharmacol. 1983;25(5):683-7. doi: 10.1007/BF00542359.
6
Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study.血液透析患者静脉注射伊班膦酸盐的清除率：一项单中心开放性研究。
Nephrol Dial Transplant. 2002 Jul;17(7):1281-5. doi: 10.1093/ndt/17.7.1281.
7
Propranolol disposition in renal failure.肾衰竭时普萘洛尔的处置
Br J Clin Pharmacol. 1980 Dec;10(6):561-6. doi: 10.1111/j.1365-2125.1980.tb00511.x.
8
Total and free steady-state plasma levels and pharmacokinetics of nifedipine in patients with terminal renal failure.终末期肾衰竭患者硝苯地平的总稳态血浆水平、游离稳态血浆水平及药代动力学
Eur J Clin Pharmacol. 1989;37(2):185-9. doi: 10.1007/BF00558229.
9
Plasma concentrations of nifedipine in patients with renal failure.肾衰竭患者硝苯地平的血浆浓度。
Arzneimittelforschung. 1984;34(3):307-8.
10
Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.阿替洛尔在终末期肾衰竭患者中的药代动力学及血液透析的影响。
Br J Clin Pharmacol. 1980 Apr;9(4):379-85. doi: 10.1111/j.1365-2125.1980.tb01065.x.
引用本文的文献
1
Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis.纳曲酮在接受血液透析患者中的药代动力学及透析性
Eur J Drug Metab Pharmacokinet. 2004 Oct-Dec;29(4):225-30. doi: 10.1007/BF03190603.
2
Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.维拉帕米、硝苯地平和地尔硫䓬的临床药代动力学。
Clin Pharmacokinet. 1986 Nov-Dec;11(6):425-49. doi: 10.2165/00003088-198611060-00002.
3
Pharmacokinetics of nisoldipine in renal dysfunction.尼索地平在肾功能不全患者中的药代动力学。
Eur J Clin Pharmacol. 1988;34(2):207-9. doi: 10.1007/BF00614560.
4
Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.钙通道拮抗剂：第六部分：第一代和第二代药物的临床药代动力学
Cardiovasc Drugs Ther. 1989 Aug;3(4):482-97. doi: 10.1007/BF01865507.
5
Inhibitory effect of uraemia on the hepatic clearance and metabolism of nicardipine.尿毒症对尼卡地平肝脏清除率及代谢的抑制作用。
Br J Clin Pharmacol. 1991 Jul;32(1):57-62. doi: 10.1111/j.1365-2125.1991.tb05613.x.
6
Pharmacokinetics of newer drugs in patients with renal impairment (Part II).
Clin Pharmacokinet. 1991 May;20(5):389-410. doi: 10.2165/00003088-199120050-00004.
7
Clinical pharmacokinetics of calcium antagonists. An update.钙拮抗剂的临床药代动力学。最新进展。
Clin Pharmacokinet. 1992 Jun;22(6):416-33. doi: 10.2165/00003088-199222060-00002.
本文引用的文献
1
Effects of nifedipine on resistance vessels, arteries and veins in man.硝苯地平对人体阻力血管、动脉和静脉的作用。
Br J Clin Pharmacol. 1980 Nov;10(5):433-8. doi: 10.1111/j.1365-2125.1980.tb01784.x.
2
Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.硝苯地平在正常受试者单次静脉注射和口服后的动力学及生物利用度。
J Clin Pharmacol. 1983 Apr;23(4):161-70. doi: 10.1002/j.1552-4604.1983.tb02720.x.
3
Nifedipine: kinetics and dynamics in healthy subjects.硝苯地平：健康受试者的动力学与动态变化
Clin Pharmacol Ther. 1984 Jun;35(6):742-9. doi: 10.1038/clpt.1984.105.
4
The first pass metabolism of nifedipine in man.硝苯地平在人体中的首过代谢。
Br J Clin Pharmacol. 1984 Dec;18(6):951-4. doi: 10.1111/j.1365-2125.1984.tb02569.x.
5
Ischaemic myocardial damage in chronic renal failure.慢性肾衰竭中的缺血性心肌损伤。
Br Med J. 1971 Oct 16;4(5780):151-2. doi: 10.1136/bmj.4.5780.151.
6
The effect of dialysis on the protein binding of drugs in the plasma of patients with acute renal failure.
Acta Pharmacol Toxicol (Copenh). 1974 Apr;34(4):284-94. doi: 10.1111/j.1600-0773.1974.tb03525.x.
7
8
Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors.
Biochem Pharmacol. 1976 May 15;25(10):1205-13. doi: 10.1016/0006-2952(76)90370-1.
9
The binding of drugs to plasma proteins from patients with poor renal function.
Clin Pharmacokinet. 1976;1(2):121-5. doi: 10.2165/00003088-197601020-00003.
10
Gas chromatographic determination of nifedipine and one of its metabolites using electron capture detection.
J Chromatogr. 1979 Jan 1;162(1):81-7. doi: 10.1016/s0378-4347(00)82066-6.
Zotero 插件